New Two-Drug attack on Tough-to-Treat sarcoma
NCT ID NCT05099666
Summary
This study is testing whether adding a newer drug, lurbinectedin, to a standard chemotherapy (doxorubicin) works better for treating advanced soft-tissue sarcoma. The first part checks the safety and best dose of the combination. The second part directly compares the new combination against the standard drug alone in patients with a specific type called leiomyosarcoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
Mayo Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.